Marijuana Moment
The Drug Enforcement Administration (DEA) has released new quotas for the production of Schedule I and Schedule II controlled substances for research purposes—calling for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA.
As DEA prepares to hold an administrative hearing in December to gain additional input on the Biden administration’s proposal to move cannabis to Schedule III of the Controlled Substances Act (CSA), the agency has posted a pair of notices, set to be published in the Federal Register on Wednesday, that outline its Aggregate Production Quotas (APQs) for a variety of drugs that could be used in approved studies.
Over recent years, DEA has generally ramped up production goals for marijuana and certain psychedelics as interest in their therapeutic potential has grown within the public and scientific community. But the revised 2024 and new 2025 proposed numbers seem to signal that, for most substances, those quotas are leveling out, at least for now.
Read full report. https://www.marijuanamoment.net/dea-calls-for-increased-production-of-some-psychedelics-for-research-as-marijuana-quotas-level-out-ahead-of-scheduling-decision/